Results 31 to 40 of about 316,660 (233)

Giant juvenile xanthogranuloma of the tongue presenting from birth in a 1-month-old infant: A case report [PDF]

open access: yes, 2018
Juvenile xanthogranuloma is a rare benign proliferative lesion of the non-Langerhans cell histiocytic group. Extracutaneous involvement is extremely rare.
Kabeer, Ahmed   +3 more
core   +5 more sources

Disseminated Juvenile Xanthogranuloma with a Novel MYH9-FLT3 Fusion Presenting as a Blueberry Muffin Rash in a Neonate

open access: yesAmerican Journal of Perinatology Reports, 2022
Juvenile xanthogranuloma (JXG) is a benign proliferative histiocytic disorder of the dendritic cell phenotype. It mostly presents in the pediatric age group as a solitary skin lesion.
Emily E. Clark   +5 more
semanticscholar   +1 more source

On the knowledge of solitary juvenile xanthogranuloma of the eyelid: a case series and literature review

open access: yesGraefe's Archive for Clinical and Experimental Ophthalmology, 2022
Solitary eyelid juvenile xanthogranuloma (JXG) is extremely rare, and there is limited literature on its clinical features and treatment outcomes. Here, we present a case series and comprehensive review of the literature on patients with isolated eyelid ...
Rongxin Chen   +7 more
semanticscholar   +1 more source

Upper eyelid juvenile xanthogranuloma: a case report

open access: yesRevista Brasileira de Oftalmologia, 2021
Juvenile xanthogranuloma is a rare benign non-Langerhans cell histiocytosis. Clinical manifestation usually occurs up to the age of 2 years, with yellowish papules and variable clinical progression.
Pedro Henrique Oliveira Ribeiro   +4 more
doaj   +1 more source

Solitary juvenile xanthogranuloma of temporal bone: a case report

open access: yesBMC Pediatrics, 2022
Background Juvenile xanthogranuloma (JXG) is a kind of non-Langerhans cell histiocytosis, usually with skin lesions as the main manifestation. It rarely occurs in other tissues or organs and even more rarely is it found in the skull.
Shu-ni Wang, Ji Lu
semanticscholar   +1 more source

Neuroimaging in Pediatric Patients with Juvenile Xanthogranuloma of the CNS

open access: yesAmerican Journal of Neuroradiology, 2022
BACKGROUND AND PURPOSE: Juvenile xanthogranuloma is a rare clonal, myeloid, neoplastic disorder. Typically, juvenile xanthogranuloma is a self-limited disorder of infancy, often presenting as a solitary red-brown or yellow skin papule/nodule.
B. Serrallach   +11 more
semanticscholar   +1 more source

Case series of volar juvenile xanthogranuloma: Clinical observation of a peripheral rim of hyperkeratosis [PDF]

open access: yes, 2014
Juvenile xanthogranuloma is a benign histiocytic tumor predominantly occurring in children as yellowish papules on the head and trunk. Presentations on the volar surfaces are rare and may cause diagnostic confusion with pyogenic granuloma, eccrine poroma
Amadi, Ugochukwu   +7 more
core   +1 more source

A comparison of the International Consensus and 5th WHO classifications of T‐cell lymphomas and histiocytic/dendritic cell tumours

open access: yesBritish Journal of Haematology, Volume 203, Issue 3, Page 369-383, November 2023., 2023
The simultaneous existence of two classifications of haemato‐lymphoid tumours poses problems not only for diagnosis formulation but also for patients' management and design of clinical trials. Summary Since the publication in 2017 of the revised 4th Edition of the World Health Organization (WHO) classification of haematolymphoid tumours, here referred ...
Brunangelo Falini   +2 more
wiley   +1 more source

Cardiac Juvenile Xanthogranuloma in an Infant Presenting with Pericardial Effusion [PDF]

open access: yes, 2012
Juvenile xanthogranuloma is a rare histiocytic disorder of childhood mainly affecting skin and rarely deep soft tissues and viscera. We report a 2‐month‐old infant who presented with respiratory distress secondary to a large pericardial effusion ...
Aggarwal, Sanjeev   +3 more
core   +1 more source

Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms

open access: yesBritish Journal of Haematology, Volume 203, Issue 3, Page 389-394, November 2023., 2023
17/22 (77%) of patients with histiocytic neoplasms undergoing interruption of targeted therapy experience disease relapse. Summary Little is known about outcomes following interruption of targeted therapy in adult patients with histiocytic neoplasms. This is an IRB‐approved study of patients with histiocytic neoplasms whose BRAF and MEK inhibitors were
Anne S. Reiner   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy